Skip to content
TrialScanner

NCT05125068

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Phase 2TerminatedELDNLead

Registry record

Lead sponsor
Eledon Pharmaceuticals
Conditions
IgA Nephropathy; IgAN
Primary completion
Jul 31, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05125068 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05125068: Safety and Efficacy of... | TrialScanner